Nonprescription headache remedies save consumers $4.23 bil. annually -- Kline study.
This article was originally published in The Tan Sheet
Executive Summary
Rx-to-OTC SWITCH PRODUCTS SAVED CONSUMERS $12.88 BIL. IN 1996, according to a study conducted by Fairfield, N.J.-based Kline & Company for the Nonprescription Drug Manufacturers Association. Presented at NDMA's May 15-18 annual meeting in White Sulphur Springs, W.Va., the study found that the savings generated by switch products represented 63% of the total savings attributable to OTCs. "It is clear that the Rx-to-OTC switch process contributes greatly to the continued value of OTC products," Kline maintained
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.